FDA approves Moderna’s mRNA flu shot for adults 50+, after initial review reversal
TL;DR Summary
The FDA has approved Moderna's mRNA seasonal flu vaccine, mFlusiva (mRNA-1010), for adults 50 and older after initially declining to review the application; Phase 3 data show the vaccine is superior to standard vaccines in preventing influenza-like illness in adults 50+, with more mild adverse events, and approvals cover ages 50-64 (and accelerated approval for those 65 and older).
- FDA Approves Moderna's mRNA Flu Vaccine After Initially Refusing To Review It Engadget
- A new type of flu shot is coming after FDA approves mRNA-based vaccine The Washington Post
- FDA Approves First mRNA Flu Vaccine in Win for Moderna After Arduous Review WSJ
- U.S. missile stockpiles dwindle. And, FDA weighs approval of flu shots with mRNA tech NPR
- One year since Kennedy canceled mRNA vaccine projects, science shows how wrong he was statnews.com
Reading Insights
Total Reads
0
Unique Readers
21
Time Saved
3 min
vs 4 min read
Condensed
91%
626 → 59 words
Want the full story? Read the original article
Read on Engadget